Best Penny Stocks Under $1.00 Right Now

The stock market has had an incredible bull-run since the Great Recession of 2008 and 2009. While stocks are no longer hitting new all-time highs, the price-to-earnings ratios of most S&P 500 companies still look somewhat expensive historically speaking. Many investors are having trouble finding low-priced stocks that have great business fundamentals and actually generate cash flow.

Stocks have gotten expensive both in-terms of share price and their valuation relative to earnings. In more normal markets, a typical S&P 500 company has traded at about fifteen times their earnings. Most stocks are currently trading closer to 20 times their annual earnings. While the stock market is more expensive as a whole than it has been historically, there are still a handful of undervalued stocks that are trading at less than $1.00 per share.

Value investing opportunities do exist if you're looking in the right places. Putting together a list of the best stocks under $1.00 requires investors to look at smaller and riskier companies and in sectors that are either undiscovered or unloved by the market as a whole. Some of these cheap stocks may not look especially attractive today, but long-term investors will profit if they are willing to exercise patience and hold on to shares of these comapnies through multiple economic cycles.

Some of these companies are solid investing ideas because they are too little and considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unloved and untested areas of the market. You may find even find crypto stocks, marijuana stocks, and biotechnology stocks on this list. Others have been beat up by Mr. Market after a long period of slowing profits, but are now actively trying to turn around their business and bounce back. These low-priced stocks operate in a lot of different industries, but these picks all carry two common characteristics. They all have a super-low share price of $1.00 (1 dollar) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

#1 - Cidara Therapeutics

NASDAQ:CDTX
Stock Price: $0.68 (+$0.01)
PE Ratio: -0.62
Market Cap: $46.95 million
Average Trading Volume: 323,905 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $6.45 (848.5% Upside)

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

#2 - Syros Pharmaceuticals

NASDAQ:SYRS
Stock Price: $0.69 (+$0.01)
PE Ratio: -0.40
Market Cap: $43.48 million
Average Trading Volume: 415,795 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $12.00 (1,639.1% Upside)

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

#3 - Sientra

NASDAQ:SIEN
Stock Price: $0.65 (+$0.04)
PE Ratio: -0.70
Market Cap: $40.81 million
Average Trading Volume: 1.01 million shares
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $6.63 (919.2% Upside)

Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products in the United States and internationally. It offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra Round, Sientra Teardrop, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. The company also provides body contouring products; facial and nasal implants; saline filled sizers. It serves to hospitals, surgery centers, plastic surgeons, dermatologists and other specialties. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.

#4 - Unity Biotechnology

NASDAQ:UBX
Stock Price: $0.48 (+$0.01)
PE Ratio: -0.50
Market Cap: $33.29 million
Average Trading Volume: 10.77 million shares
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $7.20 (1,406.6% Upside)

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

#5 - Applied Genetic Technologies

NASDAQ:AGTC
Stock Price: $0.41 (-$0.01)
PE Ratio: -0.28
Market Cap: $20.55 million
Average Trading Volume: 967,279 shares
Consensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $15.00 (3,603.7% Upside)

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was incorporated in 1999 and is headquartered in Alachua, Florida.

#6 - Integra Resources

NYSEMKT:ITRG
Stock Price: $0.60 (+$0.02)
PE Ratio: -1.37
Market Cap: $46.16 million
Average Trading Volume: 97,598 shares
Consensus Rating: Buy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $4.13 (584.1% Upside)

Integra Resources Corp., a mineral resources company, engages in the acquisition, exploration, and development of mineral properties in the Americas. It primarily focuses on the development of DeLamar project that consists of DeLamar and Florida Mountain gold and silver deposits comprising 790 unpatented lode, placer, and millsite claims, as well as 16 tax parcels covering an area of approximately 8,673 hectares located in the Owyhee County, south western Idaho. The company was formerly known as Mag Copper Limited and changed its name to Integra Resources Corp. in August 2017. Integra Resources Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.

#7 - Tidewater Midstream and Infrastructure

OTCMKTS:TWMIF
Stock Price: $0.93
Average Trading Volume: 24,089 shares
Consensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $1.84 (98.9% Upside)

Tidewater Midstream and Infrastructure Ltd., through its subsidiaries, operates as a diversified midstream and infrastructure company in North America. It primarily focuses on natural gas, natural gas liquids (NGLs), and crude oil operations and processing plants located in the Deep Basin, Edmonton, and Montney regions of Alberta and British Columbia. The company engages in gathering, processing, and transportation for natural gas and NGLs; crude oil refining and refined products marketing; NGL extraction and marketing; and crude oil marketing and transportation. It also produces refined products, including gasoline, low sulfur diesel, and other products; produces and sells crude oil, natural gas, and NGLs; and rents railcar, as well as operates export terminals and storage facilities. The company was incorporated in 2015 and is headquartered in Calgary, Canada.

#8 - Marathon Gold

OTCMKTS:MGDPF
Stock Price: $0.96
Average Trading Volume: 48,881 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $2.92 (204.4% Upside)

Marathon Gold Corporation engages in the acquisition, exploration, and development of mineral resource projects in Canada. The company explores for gold, and precious and base metal deposits. Its flagship property is the Valentine Lake gold property with four mineralized deposits located in Newfoundland and Labrador, Canada. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

#9 - China Overseas Property

OTCMKTS:CNPPF
Stock Price: $0.95
Average Trading Volume: 1,982 shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: N/A

China Overseas Property Holdings Limited, an investment holding company, provides property management services in Hong Kong, Macau, and the People's Republic of China. It operates through Property Management Services, Value-Added Services, and Car Parking Spaces Trading Business segments. The Property Management Services segment offers security, repair and maintenance, cleaning, and garden landscape maintenance services to mid-to high-end residential communities, commercial properties, government properties, and construction sites. The Value-Added Services segment offers engineering, vetting of building plans, facilities and equipment evaluation proposals, pre-delivery, move-in assistance, delivery inspection, engineering service quality monitoring and consulting services, etc. for property developers and other property management companies; and community asset management services and living service operations for residents, as well as commercial service operations. The Car Parking Spaces Trading Business segment engages in the trading of various car parking spaces. It is also involved in the provision of automation and other equipment upgrade services; property agency; information technology services; and service through online to offline platform. The company was formerly known as China Overseas Management Services International Limited and changed its name to China Overseas Property Holdings Limited in May 2015. The company was founded in 1986 and is headquartered in Hong Kong, Hong Kong. China Overseas Property Holdings Limited is a subsidiary of China Overseas Holdings Limited.

#10 - Petrofac

OTCMKTS:POFCY
Stock Price: $0.60
Market Cap: $625.39 million
Average Trading Volume: 4,992 shares
Consensus Rating: Buy (6 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $153.33 (25,455.6% Upside)

Petrofac Limited designs, builds, manages, and maintains infrastructure for the energy industries in the United Kingdom, Algeria, Thailand, Oman, Kuwait, Iraq, the United Arab Emirates, the Netherlands, and internationally. It operates through three segments: Engineering & Construction (E&C); Asset Solutions; and Integrated Energy Services (IES). The E&C segment provides onshore and offshore engineering, procurement, construction, installation, and commissioning services. The Asset Solutions segment offers concept, feasibility, and front-end engineering design services, as well as manages and maintains onshore and offshore operations. The IES segment provides an integrated services for clients under flexible commercial models that are aligned with their requirements. Petrofac Limited was founded in 1981 and is based in St Helier, Jersey.

#11 - Freeline Therapeutics

NASDAQ:FRLN
Stock Price: $0.85 (+$0.00)
PE Ratio: -0.31
Market Cap: $55.24 million
Average Trading Volume: 41,791 shares
Consensus Rating: Buy (5 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $10.00 (1,076.2% Upside)

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

#12 - Cabaletta Bio

NASDAQ:CABA
Stock Price: $0.98 (-$0.03)
PE Ratio: -0.53
Market Cap: $28.32 million
Average Trading Volume: 3.37 million shares
Consensus Rating: Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $10.80 (1,006.4% Upside)

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

#13 - OncoCyte

NYSEAMERICAN:OCX
Stock Price: $0.80 (+$0.03)
PE Ratio: -1.04
Market Cap: $94.89 million
Average Trading Volume: 487,523 shares
Consensus Rating: Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $2.94 (267.5% Upside)

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

#14 - eFFECTOR Therapeutics

NASDAQ:EFTR
Stock Price: $0.54 (+$0.03)
PE Ratio: 0.71
Market Cap: $22.33 million
Average Trading Volume: 606,764 shares
P/E Ratio: 0.7
Consensus Rating: Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $18.24 (3,280.9% Upside)

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.

#15 - CubicFarm Systems

OTCMKTS:CUBXF
Stock Price: $0.15 (+$0.01)
Average Trading Volume: 22,764 shares
Consensus Rating: Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $1.18 (688.9% Upside)

CubicFarm Systems Corp. develops, manufactures, and sells cubic farming systems for farmers worldwide. The company offers CubicFarm System and CubicFarms' HydroGreen Grow System. Its systems help farmers to produce lettuce, basil, microgreens, nutraceutical ingredients, and animal feed. The company was formerly known as Forty Foot Farms Ltd. and changed its name to CubicFarms Systems Corp. in June 2016. CubicFarms Systems Corp was incorporated in 2015 and is headquartered in Langley, Canada.

#16 - Centamin

OTCMKTS:CELTF
Stock Price: $0.96 (-$0.13)
Market Cap: $1.11 billion
Average Trading Volume: 5,795 shares
Dividend Yield: 4.59%
Consensus Rating: Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $136.50 (14,109.9% Upside)

Centamin plc engages in the exploration, mining, and development of precious metals in Egypt, Burkina Faso, Côte d'Ivoire, Jersey, the United Kingdom, and Australia. The company explores for gold deposits. Its principal asset is the Sukari Gold Mine project, which covers an area of approximately 160 square kilometers located in the Eastern Desert of Egypt. The company was incorporated in 2011 and is headquartered in Saint Helier, Jersey.

#17 - Cybin

OTCMKTS:CYBN
Stock Price: $0.94 (-$0.03)
PE Ratio: -3.02
Market Cap: $156.91 million
Average Trading Volume: 1.62 million shares
Consensus Rating: Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $7.67 (718.8% Upside)

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

#18 - Skylight Health Group

NASDAQ:SLHG
Stock Price: $0.51
Market Cap: $19.97 million
Average Trading Volume: 94,678 shares
Consensus Rating: Buy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.50 (987.8% Upside)

Skylight Health Group Inc. operates as a healthcare services and technology company in the United States, Canada, the United Kingdom, and Colombia. It operates the US multi-state primary care health network, which provides a range of services from primary care, sub-specialty, allied health, and laboratory/diagnostic testing. The company also owns and operates a proprietary electronic health record system that supports the delivery of care to patients through telemedicine and other remote monitoring system integrations. In addition, it offers a disruptive subscription-based telemedicine service for the un/under-insured population. The company was formerly known as CB2 Insights Inc. and changed its name to Skylight Health Group Inc. in November 2020. Skylight Health Group Inc. was founded in 2014 and is headquartered in Mississauga, Canada.

#19 - Forterra

OTCMKTS:FTTRF
Stock Price: $0.00
Average Trading Volume: 23,883 shares
Consensus Rating: Buy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $289.00 (48,166,566.7% Upside)

Forterra plc manufactures and sells masonry products in the United Kingdom. It operates through three segments: Bricks, Blocks, and Bespoke Products. The company offers bricks; aircrete and aggregate blocks; and bespoke products comprising precast concrete flooring, concrete block paving, and chimney and roofing components, as well as other building products under the London Brick, Butterley Brick, Ecostock, Cradley, Thermalite, Conbloc, Bison Precast, Jetfloor, Red Bank, and Formpave brand names. It serves builders' merchants, residential homebuilders, specialized brick merchants, contractors, and subcontractors. The company was incorporated in 2016 and is headquartered in Northampton, the United Kingdom.

#20 - Tullow Oil

OTCMKTS:TUWOY
Stock Price: $0.24 (+$0.01)
Market Cap: $687.51 million
Average Trading Volume: 299,738 shares
Consensus Rating: Buy (5 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $85.00 (35,464.9% Upside)

Tullow Oil plc engages in the oil and gas exploration, development, and production activities primarily in Africa and South America. As of December 31, 2021, its portfolio comprised 30 licenses in 8 countries with 30 producing wells. The company was founded in 1985 and is headquartered in London, the United Kingdom.

#21 - Argonaut Gold

OTCMKTS:ARNGF
Stock Price: $0.37 (+$0.02)
Average Trading Volume: 187,138 shares
Consensus Rating: Buy (2 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $1.14 (206.5% Upside)

Argonaut Gold Inc. is a Canadian company engaged in gold mining, mine development, and mineral exploration activities at gold-bearing mineral properties in North America. Its primary assets include the El Castillo and San Agustin mines, which together form the El Castillo Complex located in Durango, Mexico; the La Colorada mine located in Sonora, Mexico; the Florida Canyon mine in Nevada, the United States; and the Cerro del Gallo project in Guanajuato, Mexico. The advanced exploration projects of the company include the San Antonio project in Baja California Sur, Mexico, the Cerro del Gallo project in the State of Guanajuato, Mexico, the Ana Paula project in the State of Guerrero, Mexico, and the Magino project in the Province of Ontario, Canada. The Company also holds several other exploration stage projects, all of which are located in North America. Argonaut Gold Inc. was founded in 2007 and is headquartered in Reno, Nevada.

#22 - AVROBIO

NASDAQ:AVRO
Stock Price: $0.88 (+$0.01)
PE Ratio: -0.32
Market Cap: $38.48 million
Average Trading Volume: 176,531 shares
Consensus Rating: Buy (4 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.29 (501.3% Upside)

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

#23 - Galiano Gold

NYSEMKT:GAU
Stock Price: $0.49 (+$0.02)
PE Ratio: -1.47
Market Cap: $105.72 million
Average Trading Volume: 331,924 shares
Consensus Rating: Buy (2 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $1.06 (117.1% Upside)

Galiano Gold Inc. engages in the exploration, development, and production of gold properties. The company's primary asset is the Asanko Gold Mine located in Ghana, West Africa. The company was formerly known as Asanko Gold Inc. and changed its name to Galiano Gold Inc. in May 2020. Galiano Gold Inc. was incorporated in 1999 and is headquartered in Vancouver, Canada.

#24 - Gold Standard Ventures

NYSEAMERICAN:GSV
Stock Price: $0.40
PE Ratio: -13.40
Market Cap: $144.21 million
Average Trading Volume: 580,077 shares
Consensus Rating: Buy (2 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $0.84 (109.8% Upside)

Gold Standard Ventures Corp., an exploration stage company, engages in the development of district-scale and other gold-bearing mineral resource properties in Nevada, the United States. Its flagship property is the Railroad-Pinion project covering an area of approximately 53,570 acres located in the Elko County, Nevada. The company was incorporated in 2004 and is headquartered in Vancouver, Canada. As of August 12, 2022, Gold Standard Ventures Corp operates as a subsidiary of Orla Mining Ltd.

#25 - CaixaBank

OTCMKTS:CAIXY
Stock Price: $0.96 (+$0.03)
Market Cap: $23.13 billion
Average Trading Volume: 550,078 shares
Dividend Yield: 4.04%
Consensus Rating: Buy (5 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $3.66 (283.0% Upside)

CaixaBank, S.A., together with its subsidiaries, provides various banking products and financial services in Spain and internationally. The company operates through Banking and Insurance, Equity Investments, and BPI segments. It also provides solutions related to security, protection, internationalization, and financing; traditional financial advice, independent advice, and broker services; asset management; liquidity management; capital markets, cash management, project finance, asset finance, and M&A services; and various financial services and solutions to public and private sector institutions, as well as distributes non-life and life risk insurance policies; and private banking services. In addition, the company is involved in the real estate business. As of September 30, 2021, it had 5,415 branches and 13,678 ATMs in Spain; and 316 branches and 1,440 ATMs in Portugal. CaixaBank, S.A. was founded in 1904 and is based in Valencia, Spain.

More Stock Ideas from MarketBeat

Stock Lists:

Cheap Stocks:

Stocks By Exchange:

Latest Stock Ideas:

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial Subscription Here